Keywords: Ligand Pharma, Retrophin. Orphan kidney disease indicationa, DARA

Ligand licenses DARA Program to Retrophin

Article | 21 February 2012

Print This

USA-based Ligand Pharmaceuticals (Nasdaq: LGND) has entered into an agreement in which it has licensed rights to DARA (a Dual ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in